Neuropace (NPCE) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.18

Estimate

-$0.19

Surprise

+5.6%

Revenue (period 2026-06-30)

$22.8M

Score today

5.4/10

Revenue source: xbrl.

Neuropace (NPCE) reported a narrower loss than forecast — diluted EPS of -$0.18 against the -$0.19 estimate (a 5.6% beat on a still-unprofitable quarter).

• NeuroPace Raises FY2026 Sales Guidance from $99.000M-$101.000M to $99.500M-$101.500M vs $99.913M Est — benzinga, 2026-08-11
• NeuroPace Q2 EPS $(0.18) Beats $(0.20) Estimate, Sales $22.826M Beat $22.654M Estimate — benzinga, 2026-08-11

TrendMatrix currently rates NPCE Sell at 5.4/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +5.6% surprise compares with a +19.4% four-quarter average. Next scheduled report: 2026-11-03.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$14.90

Price target

$17.59

Stop

$13.86

Upside to target

+18.1%

Reward-to-risk

2.0:1

Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Devices

Market cap

$511.4M

P/E (fwd)

-67.1

52-week range

$9.22–$19.60

Off 52-week high

24.0%

RSI (14)

58

Volume vs avg

0.60×

Score today

5.4/10